19.01.2022, Author: Carsten Mainitz

Cardiol Therapeutics - shares with blockbuster potential — Study demonstrates cannabinoids from cannabis effective in treating COVID-19

  • Covid
  • Life Science
  • Cannabinoid
  • Cannabidiol
  • Health

Humanity is still caught up in the covid pandemic. The shares of vaccine manufacturers have skyrocketed. Despite great successes in combating the pandemic, there are also downsides. These are secondary damages, such as damage to the heart. This is where the Canadian company Cardiol Therapeutics comes in. The company is currently undergoing promising clinical trials with preparations based on cannabidiol that are intended to treat inflammatory heart disease. Recent research shows that cannabis ingredients can prevent infection with the Corona virus by blocking its entry into cells. This suggests that Cardiol’s preparations could have blockbuster potential. Analysts unanimously believe that the shares, which are also listed on the NASDAQ, have the potential to multiply.

ISIN: CA14161Y2006
Last CAD 2,82
Number of shares 61,922,999
Market capitalization CAD 174,622,857
Main stock exchanges Toronto, NASDAQ
Industry Life Science
Therapeutic areas / research pipeline Cannabidiol therapies for inflammatory heart disease, COVID
Founded 2017
CEO David Elsley
Source: Cardiol Therapeutics, S&P CapitalIQ Pro, as of 01/18/2022
heart exam
Heart disease is one of the biggest medical problems. Source: Cardiol Therapeutics.

State of the art research - profile

Cardiol Therapeutics is a platform drug company developing a synthetic cannabidiol (CBD)-based liquid drug. The formulation, known as CardiolRx™, is being evaluated for the treatment of various life-threatening cardiovascular conditions. Heart failure alone costs approximately USD 30 billion annually in the U.S.

Orally administered CardiolRx is currently being investigated in a clinical Phase II/III study in patients hospitalized with COVID-19 who have a history of cardiovascular disease and/or associated risk factors."1


cannabigerolic acid and cannabidiolic acidan bind the spike protein, researchers recently found.

In addition, the company is expecting to initiate an international Phase II clinical trial of orally administered CardiolRx for the treatment of acute myocarditis. Myocarditis is a condition caused by inflammation of the heart tissue. It is a leading cause of sudden cardiac death in people under the age of 35.

CardiolRx has the same concentration but higher purity than Epidiolex®, the first FDA-approved pharmaceutical form of CBD developed as an orphan drug (extended market exclusivity of 7 to 10 years in approved markets) for the treatment of rare forms of pediatric epilepsy. From this indication, a blockbuster potential can be inferred for the Cardiol oral formulation. The third candidate currently in development is a subcutaneous (SC) formulation of CardiolRx for the treatment of chronic heart failure.

Cardiol has research collaborations with several top international centers, including Houston Methodist DeBakey Heart & Vascular Center, University of Alberta and TecSalud del Tecnológico de Monterrey, Mexico.

Cannabidiol and the impact on the cardiovascular system.

A 2016 research paper published in Molecular Medicine by WS Lee et al, which presented findings on the effect of cannabidiol on cardiac inflammation and fibrosis, demonstrated that "CBD treatment significantly attenuates autoimmune myocarditis and improves myocardial dysfunction and heart failure primarily through its anti-inflammatory and anti-fibrotic effects."

In addition, the authors concluded that "these results, combined with CBD's demonstrated safety in human clinical trials and its current FDA orphan drug approval for various neurological disorders, suggest that it has enormous therapeutic potential for the treatment of myocarditis of various etiologies and various autoimmune diseases."


This is what myocarditis looks like before and after treatment with CardiolRx's active ingredient, cannabidiol. Source: Cardiol Therapeutics.

These findings formed the approach to Cardiol's business. Science is still working to understand the entire life cycle of CBD in the human body and its interaction with its various components. What is looking more and more certain however, is CBD causes vasodilatation, lowers blood pressure, and protects the heart.

Current study on Covid-19 has signal character


Ingredients can prevent infection with the virus that causes covid-19 by blocking its entry into cells.

Recently, researchers at Oregon State University published a study of great signaling character. The experts found that ingredients of cannabis prevent infection with the virus that causes Covid-19 by blocking its entry into cells.3 The researchers discovered that cannabigerolic acid and cannabidiolic acid can bind to the spike protein of SARS-CoV-2, the virus that causes covid-19. "These cannabinoids, isolated or in hemp extracts, are orally bioavailable and have a long history of safe use in humans. They have the potential to prevent and treat SARS-CoV-2 infection," the researchers said in their summary of the study.


Safety Issue #1.

Unlike other cannabinoids, CBD has an exceptional safety profile and poses no significant risk to users. To date, studies with CBD have shown none of the adverse effects associated with other cannabinoids such as THC. Compared to other cannabinoids, CBD also shows no evidence of abuse risk. Orally ingested CBD behaved like a placebo in all tests assessing dependence. Cannabidiol generally has low toxicity, no effects on most non-tumor cells, psychological or biochemical parameters.

Cannabidiol is superior to many other cannabinoids. Source: Cardiol Therapeutics.

Concentration and purity

Cannabidiol can either be derived from the cannabis plant, produced biosynthetically e.g. with yeast, or synthesized pharmaceutically. Cardiol Therapeutics uses synthesized cannabidiol. For this purpose, an exclusive supply agreement was signed with Dalton Pharma Services of Toronto (Dalton) in June 2017.

Cannabidiol - CBD

A cannabinoid from the female hemp. Anticonvulsant, anti-inflammatory, anti-anxiety and anti-nausea effects have been described.

Dalton is a leading North American cGMP pharmaceutical manufacturer. At the time of the agreement, Dalton was the only Health Canada-approved and FDA-registered company in Canada licensed to manufacture pharmaceutical cannabidiol. Dalton's unique manufacturing process allows it to produce CBD of the highest purity for highly concentrated oral formulations with virtually undetectable THC content (<10ppm) on the market.

The cannabidiol formulation produced by Dalton is characterized by two features: high concentration and high purity. This is crucial for FDA approvals. All of Cardiol Therapeutics’ formulations are based on CBD formulations produced by Dalton at a concentration of 100 mg cannabidiol per ml. Using such high concentrations can reduce stress and anxiety, has high antioxidant content, and enhance anti-arthritic and anti-inflammatory effects that can help relieve inflammatory pain.

The highly concentrated, pharmaceutically produced cannabidiol formulation is said to have applications in several cardiovascular diseases. Source: Cardiol Therapeutics.

CardiolRx™ - the foundation of Cardiol Therapeutics' pharmaceutical developments.

Cardiol Therapeutics' focus is on CardiolRx™, a highly concentrated, pharmaceutically produced cannabidiol-based therapeutic used for a variety of treatments for various cardiovascular conditions.

While development of the drug for the treatment of diastolic heart failure is still in the preclinical phase, clinical trials have begun for the other two research vectors. Phase I for the treatment of acute myocarditis has been completed. The clinical trial for the treatment of patients suffering from COVID-19 with a history or risk factors for cardiovascular disease is a potentially pivotal Phase II/III trial. Phase III trials are the final step before regulatory review and approval.

Cardiol's product pipeline is well filled. Source: Cardiol Therapeutics

Smart business strategy

The usual pharmaceutical business model does not apply to Cardiol Therapeutics. Typically, drug development involves the discovery, development and launch steps. Cardiol Therapeutics took a different approach. The Canadians focused on the known anti-inflammatory properties of cannabidiol and skipped the entire discovery phase. The company then explored the inflammatory states of cardiac tissue and developed therapeutic candidates that can correct or offset these cardiac limitations.

This results in significant savings in time and investment costs. The company benefits from the collective efforts of the scientific community, allowing it to minimize risks and dramatically increase the chances of market readiness.

Cardiol-CEO David Elsley: "The listing on NASDAQ is an important milestone for our company, as NASDAQ is the world's leading exchange for life science and biotechnology companies. Source: Cardiol Therapeutics.

Investment Highlights

  • Solid financing through capital increase of USD 50 million
  • Potential takeover candidate
  • Undervaluation also in terms of competition
  • Analyst price targets up to CAD 17.49 per share
  • Blockbuster potential of product pipeline
  • Promising clinical studies
  • Cannabidiol with promising cardiac and covid applications
  • Large addressable markets
  • Low-risk corporate strategy
  • Extensive international research collaborations

Analysts see significant upside

Cardiol's share price performance over 3 years - It could be on the verge of a significant breakout. Source: S&P CapitalIQ Pro

Given the high potential and large addressable market, all four analysts attest to great upside for Cardiol’s stock. Costs related just to heart failure amount to USD 30 billion annually in the U.S. alone.

Even if Cardiol, according to the experts, should only pass the sales mark of CAD 100 million in 2027 or 2028, the share price is currently dramatically undervalued, even when compared to competitors. **The price targets of the analysts range between CAD 5.00 and CAD 15.49. with an average price target of CAD 11.00, which would be a four time increase from the current share price.

6.7 billion USD

This is how much Pfizer wants to pay for the acquisition of a company in the sector.

The possibility of a takeover of Cardiol should not be forgotten. With a market capitalization of only about CAD 170 million, Cardiol is a lightweight compared to billion-dollar acquisitions made in the past. Most recently, the US corporation Pfizer swallowed the California-based Arena Pharmaceuticals for USD 6.7 billion. Arena has yet to bring a drug to market. This company has several products in clinical development in the fields of gastroenterology, dermatology and cardiovascular diseases.

Cardiol's product pipeline has blockbuster potential. The use of cannabidiol in heart disease has great potential for success. In addition, recent research suggests that active cannabinoid ingredients may prevent covid infection. Investors are still able to get exposure to this exciting company at a favorable level. Analysts believe the stock is capable of at least quadrupling. More information is expected from the company at the International Investment Forum (IIF), Feb. 17, 2022. Free to attend:

  1. Company statement.
  2. Company statement Adapted from Lee W-S et al. (2016). Mol. Med. 22, 136-146
  3. Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants

Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

Source: Cardiol Therapeutics

ISIN: CA14161Y2006
Last CAD 2,82
Number of shares 61,922,999
Market capitalization CAD 174,622,857
Main stock exchanges Toronto, NASDAQ
Industry Life Science
Therapeutic areas / research pipeline Cannabidiol therapies for inflammatory heart disease, COVID
Founded 2017
CEO David Elsley
Source: Cardiol Therapeutics, S&P CapitalIQ Pro, as of 01/18/2022
Media comments

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

More about the author

Further analyses